Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
January 17, 2023 16:05 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
January 03, 2023 08:00 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
November 29, 2022 15:30 ET
|
Allogene Therapeutics, Inc.
Hematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in Relapsed/Refractory...
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2022 09:00 ET
|
Allogene Therapeutics, Inc.
Promising Preclinical Data Highlights a Simple One-Step Gene Editing Strategy to Prevent the Rejection of AlloCAR T™ Cells by Host T Cells and NK Cells Cloaking Approach Demonstrates Superiority to...
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
November 09, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
November 03, 2022 09:04 ET
|
Allogene Therapeutics, Inc.
ALLO-715, an Allogeneic BCMA CAR T Candidate Dosed with an ALLO-647 Based Lymphodepletion Regimen, Continues to Demonstrate a Promising Clinical ProfileA Company Sponsored R&D Showcase on November...
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
November 02, 2022 16:02 ET
|
Allogene Therapeutics, Inc.
Initiated the Industry’s First Allogeneic CAR T Phase 2 Trial ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and...
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
October 31, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
GMP Site Designed to Enable Potential Clinical and Commercial Production of AlloCAR T™ Products for Patients in Greater China, Taiwan, South Korea and Singapore SOUTH SAN FRANCISCO, Calif., Oct. 31,...
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
October 26, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...